Anandamide

Anandamide is a lipid of Fatty Acyls (FA) class. Anandamide is associated with abnormalities such as Dehydration. The involved functions are known as Process, Phenomenon, Phosphorylation, Catabolic Process and Gene Expression. Anandamide often locates in Nuchal region, Microglial and Hepatic. The associated genes with Anandamide are SGPL1 gene, SPTLC1 gene, RPSA gene, KDSR gene and SMPD1 gene. The related lipids are Sphingolipids, Lipopolysaccharides, Lysophospholipids, LYSO-PC and lysophosphatidylethanolamine.

Cross Reference

Introduction

To understand associated biological information of Anandamide, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Anandamide?

Anandamide is suspected in Dehydration and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Anandamide

MeSH term MeSH ID Detail
Stomach Ulcer D013276 75 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Neovascularization, Pathologic D009389 39 associated lipids
Breast Neoplasms D001943 24 associated lipids
Neoplasms D009369 13 associated lipids
Pain D010146 64 associated lipids
Inflammation D007249 119 associated lipids
Reperfusion Injury D015427 65 associated lipids
Colitis D003092 69 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Diabetic Retinopathy D003930 39 associated lipids
Fatty Liver D005234 48 associated lipids
Diabetes Mellitus, Experimental D003921 85 associated lipids
Body Weight D001835 333 associated lipids
Edema D004487 152 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Hypotension D007022 41 associated lipids
Prostatic Neoplasms D011471 126 associated lipids
Melanoma D008545 69 associated lipids
Weight Gain D015430 101 associated lipids
Hyperemia D006940 25 associated lipids
Hypersensitivity, Delayed D006968 43 associated lipids
Glioma D005910 112 associated lipids
Obesity D009765 29 associated lipids
Bradycardia D001919 13 associated lipids
Urinary Bladder Diseases D001745 4 associated lipids
Alzheimer Disease D000544 76 associated lipids
Thyroid Neoplasms D013964 33 associated lipids
Neuroblastoma D009447 66 associated lipids
Liver Cirrhosis D008103 67 associated lipids
Peripheral Nervous System Diseases D010523 33 associated lipids
Osteoarthritis, Knee D020370 13 associated lipids
Multiple Sclerosis D009103 13 associated lipids
Nervous System Diseases D009422 37 associated lipids
Ataxia D001259 20 associated lipids
Brain Edema D001929 20 associated lipids
Infarction, Middle Cerebral Artery D020244 35 associated lipids
Brain Ischemia D002545 89 associated lipids
Epilepsy D004827 35 associated lipids
Seizures D012640 87 associated lipids
Nerve Degeneration D009410 53 associated lipids
Peptic Ulcer D010437 19 associated lipids
Hypertension D006973 115 associated lipids
Ischemic Attack, Transient D002546 42 associated lipids
Substance-Related Disorders D019966 2 associated lipids
Hepatitis D006505 11 associated lipids
Hyperalgesia D006930 42 associated lipids
Spinal Cord Injuries D013119 34 associated lipids
Brain Damage, Chronic D001925 6 associated lipids
Ventricular Fibrillation D014693 16 associated lipids
Fever D005334 35 associated lipids
Bronchial Spasm D001986 18 associated lipids
Morphine Dependence D009021 9 associated lipids
Shock, Septic D012772 11 associated lipids
Cough D003371 19 associated lipids
Encephalomyelitis, Autoimmune, Experimental D004681 26 associated lipids
Catalepsy D002375 30 associated lipids
Migraine Disorders D008881 11 associated lipids
Cardiomyopathy, Dilated D002311 15 associated lipids
Alveolar Bone Loss D016301 10 associated lipids
Learning Disorders D007859 11 associated lipids
Hyperkinesis D006948 11 associated lipids
Hyperinsulinism D006946 27 associated lipids
Muscle Spasticity D009128 5 associated lipids
Hypothermia D007035 19 associated lipids
Celiac Disease D002446 16 associated lipids
Dyskinesia, Drug-Induced D004409 15 associated lipids
Ventricular Dysfunction, Left D018487 33 associated lipids
Hypertension, Portal D006975 12 associated lipids
Insulin Resistance D007333 99 associated lipids
Sleep Apnea, Obstructive D020181 9 associated lipids
Brain Concussion D001924 5 associated lipids
Endotoxemia D019446 27 associated lipids
Anorexia D000855 8 associated lipids
Neoplasm Invasiveness D009361 23 associated lipids
Memory Disorders D008569 33 associated lipids
Parkinson Disease, Secondary D010302 17 associated lipids
Overweight D050177 11 associated lipids
Neurodegenerative Diseases D019636 32 associated lipids
Pancreatitis, Acute Necrotizing D019283 18 associated lipids
Parkinsonian Disorders D020734 20 associated lipids
Neuralgia D009437 28 associated lipids
Fibromyalgia D005356 4 associated lipids
Hypoxia-Ischemia, Brain D020925 22 associated lipids
Intestinal Pseudo-Obstruction D007418 5 associated lipids
Mycoses D009181 18 associated lipids
Bulimia D002032 3 associated lipids
Sleep Deprivation D012892 5 associated lipids
Urinary Incontinence D014549 4 associated lipids
Vascular System Injuries D057772 2 associated lipids
Cholangiocarcinoma D018281 7 associated lipids
Amnesia, Anterograde D020324 2 associated lipids
Pregnancy, Ectopic D011271 5 associated lipids
Ocular Hypotension D015814 2 associated lipids
Sciatic Neuropathy D020426 13 associated lipids
Impotence, Vasculogenic D018783 4 associated lipids
Cardiovirus Infections D018188 3 associated lipids
Picornaviridae Infections D010850 4 associated lipids
Somatosensory Disorders D020886 1 associated lipids
Per page 10 20 50 100 | Total 105

PubChem Associated disorders and diseases

What pathways are associated with Anandamide

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Anandamide?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Anandamide?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Anandamide?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Anandamide?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Anandamide?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with Anandamide

Download all related citations
Per page 10 20 50 100 | Total 2222
Authors Title Published Journal PubMed Link
Chauvet C et al. Chronic stimulation of the tone of endogenous anandamide reduces cue- and stress-induced relapse in rats. 2014 Int. J. Neuropsychopharmacol. pmid:25522382
Malek N et al. Alterations in the anandamide metabolism in the development of neuropathic pain. 2014 Biomed Res Int pmid:25276812
De Angelis V et al. Endocannabinoids control platelet activation and limit aggregate formation under flow. 2014 PLoS ONE pmid:25264625
Özdemir B et al. Endocannabinoids and inflammatory response in periodontal ligament cells. 2014 PLoS ONE pmid:25226300
Jia J et al. Anandamide protects HT22 cells exposed to hydrogen peroxide by inhibiting CB1 receptor-mediated type 2 NADPH oxidase. 2014 Oxid Med Cell Longev pmid:25136404
Sexton M et al. Cannabis use by individuals with multiple sclerosis: effects on specific immune parameters. 2014 Inflammopharmacology pmid:25135301
Björklund E et al. Involvement of fatty acid amide hydrolase and fatty acid binding protein 5 in the uptake of anandamide by cell lines with different levels of fatty acid amide hydrolase expression: a pharmacological study. 2014 PLoS ONE pmid:25078278
Lau BK et al. Endocannabinoid modulation by FAAH and monoacylglycerol lipase within the analgesic circuitry of the periaqueductal grey. 2014 Br. J. Pharmacol. pmid:25041240
Laprairie RB et al. Type 1 cannabinoid receptor ligands display functional selectivity in a cell culture model of striatal medium spiny projection neurons. 2014 J. Biol. Chem. pmid:25037227
Cipriano M et al. The influence of monoacylglycerol lipase inhibition upon the expression of epidermal growth factor receptor in human PC-3 prostate cancer cells. 2014 BMC Res Notes pmid:25012825
Bluett RJ et al. Central anandamide deficiency predicts stress-induced anxiety: behavioral reversal through endocannabinoid augmentation. 2014 Transl Psychiatry pmid:25004388
Dong W et al. Simulation of Swanson's literature-based discovery: anandamide treatment inhibits growth of gastric cancer cells in vitro and in silico. 2014 PLoS ONE pmid:24949851
Wiley JL et al. Endocannabinoid contribution to Δ9-tetrahydrocannabinol discrimination in rodents. 2014 Eur. J. Pharmacol. pmid:24858366
Pietrzak RH et al. Cannabinoid type 1 receptor availability in the amygdala mediates threat processing in trauma survivors. 2014 Neuropsychopharmacology pmid:24820537
Ravi J et al. FAAH inhibition enhances anandamide mediated anti-tumorigenic effects in non-small cell lung cancer by downregulating the EGF/EGFR pathway. 2014 Oncotarget pmid:24811863
Hama AT et al. Fatty acid amide hydrolase (FAAH) inhibitors exert pharmacological effects, but lack antinociceptive efficacy in rats with neuropathic spinal cord injury pain. 2014 PLoS ONE pmid:24788435
Navarria A et al. The dual blocker of FAAH/TRPV1 N-arachidonoylserotonin reverses the behavioral despair induced by stress in rats and modulates the HPA-axis. 2014 Pharmacol. Res. pmid:24861565
Al Kury LT et al. Effects of the endogenous cannabinoid anandamide on voltage-dependent sodium and calcium channels in rat ventricular myocytes. 2014 Br. J. Pharmacol. pmid:24758718
Nader J et al. Prior stimulation of the endocannabinoid system prevents methamphetamine-induced dopaminergic neurotoxicity in the striatum through activation of CB2 receptors. 2014 Neuropharmacology pmid:24709540
Kaczocha M et al. Inhibition of fatty acid binding proteins elevates brain anandamide levels and produces analgesia. 2014 PLoS ONE pmid:24705380
Sun LJ et al. Endocannabinoid system activation contributes to glucose metabolism disorders of hepatocytes and promotes hepatitis C virus replication. 2014 Int. J. Infect. Dis. pmid:24704332
Jackson AR et al. Anandamide attenuates Th-17 cell-mediated delayed-type hypersensitivity response by triggering IL-10 production and consequent microRNA induction. 2014 PLoS ONE pmid:24699635
Marichal-Cancino BA et al. Role of pre-junctional CB1, but not CB2 , TRPV1 or GPR55 receptors in anandamide-induced inhibition of the vasodepressor sensory CGRPergic outflow in pithed rats. 2014 Basic Clin. Pharmacol. Toxicol. pmid:24118786
Abdulnour J et al. Circulating endocannabinoids in insulin sensitive vs. insulin resistant obese postmenopausal women. A MONET group study. 2014 Obesity (Silver Spring) pmid:23616305
Hoyer FF et al. Inhibition of endocannabinoid-degrading enzyme fatty acid amide hydrolase increases atherosclerotic plaque vulnerability in mice. 2014 J. Mol. Cell. Cardiol. pmid:24286707
Alvheim AR et al. Dietary linoleic acid elevates the endocannabinoids 2-AG and anandamide and promotes weight gain in mice fed a low fat diet. 2014 Lipids pmid:24081493
Pertwee RG Elevating endocannabinoid levels: pharmacological strategies and potential therapeutic applications. 2014 Proc Nutr Soc pmid:24135210
Burston JJ and Woodhams SG Endocannabinoid system and pain: an introduction. 2014 Proc Nutr Soc pmid:24148358
Desroches J et al. Endocannabinoids decrease neuropathic pain-related behavior in mice through the activation of one or both peripheral CB₁ and CB₂ receptors. 2014 Neuropharmacology pmid:24148808
Yang K et al. Differential regulation of NMDAR and NMDAR-mediated metaplasticity by anandamide and 2-AG in the hippocampus. 2014 Hippocampus pmid:25087967
Fezza F et al. Distinct modulation of the endocannabinoid system upon kainic acid-induced in vivo seizures and in vitro epileptiform bursting. 2014 Mol. Cell. Neurosci. pmid:25064144
Jergas B et al. O-2050 facilitates noradrenaline release and increases the CB1 receptor inverse agonistic effect of rimonabant in the guinea pig hippocampus. 2014 Naunyn Schmiedebergs Arch. Pharmacol. pmid:24853577
Pava MJ et al. Endocannabinoid modulation of cortical up-states and NREM sleep. 2014 PLoS ONE pmid:24520411
Sanson B et al. Crystallographic study of FABP5 as an intracellular endocannabinoid transporter. 2014 Acta Crystallogr. D Biol. Crystallogr. pmid:24531463
Ohno-Shosaku T and Kano M Endocannabinoid-mediated retrograde modulation of synaptic transmission. 2014 Curr. Opin. Neurobiol. pmid:24747340
Fowler CJ Has FLAT fallen flat? 2014 Trends Pharmacol. Sci. pmid:24398120
Sousa-Valente J et al. Anandamide in primary sensory neurons: too much of a good thing? 2014 Eur. J. Neurosci. pmid:24494681
Chianese R et al. Hypothalamus-pituitary axis: an obligatory target for endocannabinoids to inhibit steroidogenesis in frog testis. 2014 Gen. Comp. Endocrinol. pmid:24566122
Rea K et al. Microinjection of 2-arachidonoyl glycerol into the rat ventral hippocampus differentially modulates contextually induced fear, depending on a persistent pain state. 2014 Eur. J. Neurosci. pmid:24494683
Zheng Y et al. Dexamethasone alleviates motion sickness in rats in part by enhancing the endocannabinoid system. 2014 Eur. J. Pharmacol. pmid:24508383
Al Kury LT et al. Effects of endogenous cannabinoid anandamide on excitation-contraction coupling in rat ventricular myocytes. 2014 Cell Calcium pmid:24472666
Krishnan G and Chatterjee N Endocannabinoids affect innate immunity of Muller glia during HIV-1 Tat cytotoxicity. 2014 Mol. Cell. Neurosci. pmid:24418364
Björklund E et al. Ketoconazole inhibits the cellular uptake of anandamide via inhibition of FAAH at pharmacologically relevant concentrations. 2014 PLoS ONE pmid:24466356
Yu S et al. Fatty acid-binding protein 5 (FABP5) regulates cognitive function both by decreasing anandamide levels and by activating the nuclear receptor peroxisome proliferator-activated receptor β/δ (PPARβ/δ) in the brain. 2014 J. Biol. Chem. pmid:24644281
Mahavadi S et al. Inhibitory signaling by CB1 receptors in smooth muscle mediated by GRK5/β-arrestin activation of ERK1/2 and Src kinase. 2014 Am. J. Physiol. Gastrointest. Liver Physiol. pmid:24407588
Jackson AR et al. Characterization of endocannabinoid-mediated induction of myeloid-derived suppressor cells involving mast cells and MCP-1. 2014 J. Leukoc. Biol. pmid:24319288
Okura D et al. The endocannabinoid anandamide inhibits voltage-gated sodium channels Nav1.2, Nav1.6, Nav1.7, and Nav1.8 in Xenopus oocytes. 2014 Anesth. Analg. pmid:24557103
Harvey BS et al. Interleukin 17A evoked mucosal damage is attenuated by cannabidiol and anandamide in a human colonic explant model. 2014 Cytokine pmid:24238999
Piomelli D More surprises lying ahead. The endocannabinoids keep us guessing. 2014 Neuropharmacology pmid:23954677
Alpár A et al. Endocannabinoids modulate cortical development by configuring Slit2/Robo1 signalling. 2014 Nat Commun pmid:25030704